Disclosures for "Zorevunersen Demonstrates Potential as a Disease‑modifying Therapy in Patients with Dravet Syndrome Through Durable Seizure Reduction and Improvements in Cognition, Behavior, and Quality of Life Through 36 Months of Treatment in Open-label Extension Studies"
-
Dr. Laux has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Stoke Therapeutics. Dr. Laux has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biocodex.
-
The institution of Dr. Knupp has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Harmony. Dr. Knupp has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Epilepsy Research.
-
Prof. Brunklaus has received personal compensation in the range of $0-$499 for serving as a Consultant for Servier. Prof. Brunklaus has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Stoke Therapeutics. Prof. Brunklaus has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Stoke Therapeutics. Prof. Brunklaus has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Encoded Therapeutics. Prof. Brunklaus has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biocodex. Prof. Brunklaus has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. Prof. Brunklaus has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biocodex. Prof. Brunklaus has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for UCB.
-
Dr. Cross has nothing to disclose.
-
Dr. Perry has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for stoke therapeutics. Dr. Perry has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurelis. Dr. Perry has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Marinus. Dr. Perry has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for jazz pharmaceuticals. Dr. Perry has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for UCB. Dr. Perry has received personal compensation in the range of $500-$4,999 for serving as a Consultant for pyros. Dr. Perry has received personal compensation in the range of $500-$4,999 for serving as a Consultant for azurity. Dr. Perry has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biocodex. Dr. Perry has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Stoke Therapeutics. Dr. Perry has stock in Praxis Precision Medicine. Dr. Perry has stock in Biohaven. Dr. Perry has stock in Rapport. Dr. Perry has stock in Alto Neurosciences. Dr. Perry has a non-compensated relationship as a president with child neurology foundation that is relevant to AAN interests or activities. Dr. Perry has a non-compensated relationship as a President with Pediatric Epilepsy Research Consortium that is relevant to AAN interests or activities.
-
Dr. Sullivan has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biocodex. Dr. Sullivan has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for UCB. Dr. Sullivan has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Ceribell. Dr. Sullivan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Xenon. Dr. Sullivan has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Epilepsy Study Consortium. Dr. Sullivan has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Neuropace. Dr. Sullivan has received personal compensation in the range of $50,000-$99,999 for serving as an Expert Witness for Various firms. Dr. Sullivan has stock in Harmony.
-
Dr. Desurkar has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for biocodex. Dr. Desurkar has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for STOKE therapeutics. Dr. Desurkar has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for UCB.
-
Dr. Schreiber has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurocrine. Dr. Schreiber has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Xenon. Dr. Schreiber has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Zogenix. The institution of Dr. Schreiber has received research support from Dravet Syndrome Foundation.
-
Dr. Roberts has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurelis. Dr. Roberts has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Stoke. Dr. Roberts has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Encoded.
-
Dr. Wheless has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Jazz. Dr. Wheless has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurelis. Dr. Wheless has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Azurity. Dr. Wheless has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB. Dr. Wheless has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biocodex. Dr. Wheless has received personal compensation in the range of $500-$4,999 for serving as a Consultant for LivaNova. Dr. Wheless has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Stoke. Dr. Wheless has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for LivaNova. Dr. Wheless has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Jazz. Dr. Wheless has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for UCB. Dr. Wheless has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for UCB. Dr. Wheless has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Neurelius.
-
Dr. Wirrell has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biocodex. Dr. Wirrell has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Encoded. Dr. Wirrell has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Neurocrine. Dr. Wirrell has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for GRIN. Dr. Wirrell has received publishing royalties from a publication relating to health care.
-
Dr. Ventola has received personal compensation for serving as an employee of Cogstate. The institution of Dr. Ventola has received research support from NIH.
-
Mr. Werneburg has received personal compensation for serving as an employee of Stoke Therapeutics.
-
Mrs. Lynch has received personal compensation for serving as an employee of Stoke Therapeutics. Mrs. Lynch has stock in Stoke Therapeutics.
-
Fei Wang, PhD has received personal compensation for serving as an employee of Stoke Therapeutics.
-
Dr. Parkerson has received personal compensation for serving as an employee of Stoke Therapeutics. Dr. Parkerson has stock in Stoke Therapeutics.
-
Dr. Ticho has received personal compensation for serving as an employee of Stoke Therapeutics.